Baader Bank Aktiengesellschaft Takes $769,000 Position in Krystal Biotech, Inc. $KRYS

Baader Bank Aktiengesellschaft bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 3,163 shares of the company’s stock, valued at approximately $769,000.

A number of other hedge funds also recently modified their holdings of KRYS. Royal Bank of Canada lifted its holdings in shares of Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at $218,000. Finally, Cetera Investment Advisers lifted its holdings in shares of Krystal Biotech by 107.9% in the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after purchasing an additional 2,255 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Up 1.2%

Shares of NASDAQ:KRYS opened at $316.30 on Friday. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $319.48. The business has a fifty day simple moving average of $267.28 and a 200 day simple moving average of $252.92. The firm has a market cap of $9.32 billion, a price-to-earnings ratio of 42.29 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. The business had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, sell-side analysts forecast that Krystal Biotech, Inc. will post 7.98 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on KRYS shares. Wall Street Zen upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Bank of America increased their price objective on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $310.00 price objective on shares of Krystal Biotech in a report on Monday, May 4th. Jefferies Financial Group increased their price objective on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Finally, Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $324.11.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the transaction, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 116,664 shares of company stock valued at $31,136,828. Corporate insiders own 13.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.